HK1047881B - 治療性功能障礙的組合物 - Google Patents

治療性功能障礙的組合物

Info

Publication number
HK1047881B
HK1047881B HK02107538.2A HK02107538A HK1047881B HK 1047881 B HK1047881 B HK 1047881B HK 02107538 A HK02107538 A HK 02107538A HK 1047881 B HK1047881 B HK 1047881B
Authority
HK
Hong Kong
Prior art keywords
sexual dysfunction
compositions
treatment
phe
arg
Prior art date
Application number
HK02107538.2A
Other languages
English (en)
Other versions
HK1047881A1 (en
Inventor
H Blood Christine
M Shadiack Annette
K Bernstein Joanna
W Herbert Guy
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of HK1047881A1 publication Critical patent/HK1047881A1/xx
Publication of HK1047881B publication Critical patent/HK1047881B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02107538.2A 1999-06-29 2002-10-17 治療性功能障礙的組合物 HK1047881B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14234699P 1999-06-29 1999-06-29
US19498700P 2000-04-05 2000-04-05
US09/606,501 US6579968B1 (en) 1999-06-29 2000-06-28 Compositions and methods for treatment of sexual dysfunction
PCT/US2000/018217 WO2001000224A1 (en) 1999-06-29 2000-06-29 Compositions and methods for treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
HK1047881A1 HK1047881A1 (en) 2003-03-14
HK1047881B true HK1047881B (zh) 2005-10-14

Family

ID=27385799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107538.2A HK1047881B (zh) 1999-06-29 2002-10-17 治療性功能障礙的組合物

Country Status (15)

Country Link
US (3) US6579968B1 (zh)
EP (1) EP1196184B8 (zh)
JP (1) JP4576493B2 (zh)
KR (1) KR101021632B1 (zh)
AT (1) ATE293453T1 (zh)
AU (1) AU783718B2 (zh)
BR (1) BR0012200B1 (zh)
CA (1) CA2376978C (zh)
DE (1) DE60019598T2 (zh)
ES (1) ES2235921T3 (zh)
HK (1) HK1047881B (zh)
MX (1) MXPA02000111A (zh)
NZ (1) NZ516030A (zh)
PT (1) PT1196184E (zh)
WO (1) WO2001000224A1 (zh)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CN1571796A (zh) * 2000-09-27 2005-01-26 宝洁公司 黑皮素受体配体
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6873883B2 (en) * 2001-12-26 2005-03-29 Hewlett-Packard Development Company, L.P. Adaptive fan controller for a computer system
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
US8043287B2 (en) * 2002-03-05 2011-10-25 Kimberly-Clark Inc. Method of treating biological tissue
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
BR0305628A (pt) * 2002-07-09 2004-09-08 Palatin Technologies Inc Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
TW200500085A (en) * 2003-02-26 2005-01-01 Otsuka Pharma Co Ltd Sustained-release pharmaceutical composition for lung administration
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
TW200626611A (en) * 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
CN101257916B (zh) * 2005-07-08 2013-04-03 益普生制药股份有限公司 黑皮质素受体配体
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1957096A4 (en) * 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
CN101092451B (zh) * 2006-06-20 2011-02-09 中国人民解放军军事医学科学院毒物药物研究所 Pt-141和mt-ⅱ的固相合成方法
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
EP2056797A2 (en) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Controlled release system and method for manufacturing the same
CN101195654B (zh) * 2006-12-08 2011-06-15 上海吉尔多肽有限公司 一种美拉诺坦-ⅱ的固相合成方法
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
WO2008091355A2 (en) * 2007-01-24 2008-07-31 Breathe Pharmaceuticals, Inc. Drug transfer device
CN101280005B (zh) * 2007-04-06 2013-03-13 扬子江药业集团四川海蓉药业有限公司 普美拉肽的制备方法
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
WO2009144433A1 (en) * 2008-05-30 2009-12-03 Palatin Technologies, Inc. Methods for selection of melanocortin 4 receptor-specific agents for treatment of obesity
MX2010013436A (es) * 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
UY31877A (es) * 2008-06-09 2010-01-29 Palatin Technologies Inc Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
MX2011013117A (es) * 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CN102725305B (zh) 2009-11-23 2016-08-24 帕拉丁科技公司 黑皮质素-1受体特异性环肽
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
MX341642B (es) * 2011-06-14 2016-08-29 Ipsen Pharma Sas Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
SG11201502949QA (en) 2012-11-05 2015-06-29 Palatin Technologies Inc Bremelanotide therapy for female sexual dysfunction
AU2013348044B2 (en) 2012-11-21 2018-03-15 University Of Cincinnati Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
WO2017066769A1 (en) * 2015-10-16 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (cns) disorders and mood disorders
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN106243214B (zh) * 2016-08-29 2019-12-10 济南康和医药科技有限公司 一种美拉诺坦ⅰ的制备方法
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
WO2021158464A1 (en) * 2020-02-03 2021-08-12 Palatin Technologies, Inc. Reverse amide-linked melanocortin receptor-specific cyclic peptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) * 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US4623715A (en) * 1984-10-22 1986-11-18 Hoechst Aktiengeselleschaft Novel peptides which are active on the central nervous system and have an action on the cholinergic system
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
WO1991016929A1 (en) 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
FR2691465B1 (fr) * 1992-05-25 1995-08-11 Pf Medicament Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6228840B1 (en) 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
JP2002517444A (ja) * 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
ES2235921T3 (es) 2005-07-16
KR20020016876A (ko) 2002-03-06
US20050037951A1 (en) 2005-02-17
BR0012200B1 (pt) 2013-08-06
BR0012200A (pt) 2002-03-26
AU783718B2 (en) 2005-12-01
ATE293453T1 (de) 2005-05-15
EP1196184A1 (en) 2002-04-17
HK1047881A1 (en) 2003-03-14
JP4576493B2 (ja) 2010-11-10
EP1196184B8 (en) 2005-06-15
US6579968B1 (en) 2003-06-17
WO2001000224A1 (en) 2001-01-04
US20020107182A1 (en) 2002-08-08
PT1196184E (pt) 2005-08-31
KR101021632B1 (ko) 2011-03-17
DE60019598D1 (de) 2005-05-25
DE60019598T2 (de) 2005-09-29
EP1196184A4 (en) 2003-05-28
CA2376978A1 (en) 2001-01-04
JP2003503357A (ja) 2003-01-28
CA2376978C (en) 2012-11-20
NZ516030A (en) 2004-10-29
US6794489B2 (en) 2004-09-21
AU6340700A (en) 2001-01-31
MXPA02000111A (es) 2003-07-21
EP1196184B1 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
EP1196184B8 (en) Compositions for treatment of sexual dysfunction
WO2005014617A3 (en) Cyclic peptide compositions and methods for treatment of sexual dysfunction
CA2338005A1 (en) Peptide antagonists of zonulin and methods for use of the same
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
MY106528A (en) Method of treating impotence.
GB2326093A (en) Avermectin formulation
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
HUP0001431A2 (hu) Módosított tandem peptid, ezt tartalmazó immunogén gyógyászati készítmény és vakcina az LHRH hormon termelés ellen, és eljárás a sertéshús minőségének javítására
WO2002058589A3 (en) Agents and methods for promoting bone growth
PL336697A1 (en) Glycoconjugates 20 (s) - campthotectin
MY124560A (en) Amino acid compositions and use thereof in immunosuppression
IT1244496B (it) Impiego terapeutico dei peptidi della somatostatina.
EP1593384A3 (en) Compositions for treatment of sexual dysfunction
GB0203419D0 (en) Peptide
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
SI1442059T1 (sl) Analogi hormona, ki pospešujejo izločanje rastnega hormona, njihova priprava in uporaba
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
DK0941322T3 (da) Bovint laktationsassocieret immunotropt protein (CD14), kodende gen og anvendelse i B-celleaktivering
JPH0372044B2 (zh)
EP1372691A4 (en) MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190629